Chronic Recurrent Vogt–Koyanagi–Harada Disease and Development of ‘Sunset Glow Fundus’ Predict Worse Retinal Sensitivity

REFERENCES

• Yamaki K, Gocho K, Hayakawa K, et al. Tyrosinase family proteins are antigens specific to Vogt–Koyanagi–Harada disease. J Immunol. 2000;165:7323–7329.
   PubMed Web of Science ®Google Scholar
• Yamaki K, Kondo I, Nakamura H, et al. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res. 2000;71:361–369.
   PubMed Web of Science ®Google Scholar
• Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt–Koyanagi–Harada disease. Invest Ophthalmol Vis Sci. 2001; 42:2004–2009.
   Google Scholar
• Fang W, Yang P. Vogt–Koyanagi–Harada syndrome. Curr Eye Res. 2008;33:517–523.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt–Koyanagi–Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–614.
   PubMed Web of Science ®Google Scholar
• Al-Kharashi AS, Aldibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2007;27:201–210.
   PubMedGoogle Scholar
• Moorthy RS, Inomata H, Rao NA. Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol. 1995;39:265–292.
   PubMed Web of Science ®Google Scholar
• Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2001;131:599–606.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al-Kharashi AS, Aldibhi H, et al. Vogt–Koyanagi–Harada disease in children. Eye (Lond). 2008;22:1124–1131.
   PubMed Web of Science ®Google Scholar
• Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt–Koyanagi–Harada’s disease. Jpn J Ophthalmol. 1988;32:334–343.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493.
   PubMed Web of Science ®Google Scholar
• Al Dhahri H, Al Rubaie K, Hemachandran S, et al. Patterns of uveitis in a university-based tertiary referral center in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2014;24:1–9.
   Web of Science ®Google Scholar
• Rubsamen PE, Gass JD. Vogt–Koyanagi–Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109:682–687.
   PubMedGoogle Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2012;90:e603–e608.
   PubMed Web of Science ®Google Scholar
• Chee S-P, Jap A, Bacsal K. Spectrum of Vogt–Koyanagi–Harada disease in Singapore. Int Ophthalmol. 2007;27:137–142.
   PubMedGoogle Scholar
• Cuchacovich M, Solanes F, Diaz G, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2010;18:200–207.
   PubMed Web of Science ®Google Scholar
• Errera MH, Fardeau C, Cohen D, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt–Koyanagi–Harada disease. Acta Ophthalmol. 2011;89:e357–e366.
   PubMed Web of Science ®Google Scholar
• Sakata VM, da Silva FT, Hirata CE, et al. High rate of clinical recurrence in patients with Vogt–Koyanagi–Harada disease treated with early high-dose corticosteroids. Graefes Arch Clin Exp Ophthalmol. 2015;253:785–790.
   PubMed Web of Science ®Google Scholar
• Keino H, Goto H, Usui M. Sunset glow fundus in Vogt–Koyanagi–Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2002;240:878–882.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2007;15:381–387.
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt–Koyanagi–Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87–90.
   PubMed Web of Science ®Google Scholar
• Chee SP, Jap A, Bacsal K. Prognostic factors of Vogt–Koyanagi–Harada disease in Singapore. Am J Ophthalmol. 2009;147:154–161.
   PubMed Web of Science ®Google Scholar
• Midena E, Radin PP, Pilotto E, et al. Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry study. Semin Ophthalmol. 2004;19:55–61.
   PubMedGoogle Scholar
• Midena E, Vujosevic S, Convento E, et al. Microperimetry and fundus autofluorescence in patients with early age-related macular degeneration. Br J Ophthalmol. 2007;91:1499–1503.
   PubMed Web of Science ®Google Scholar
• Springer C, Bültmann S, Völcker HE, et al. Fundus perimetry with the Micro perimeter 1 in normal individuals: Comparison with conventional threshold perimetry. Ophthalmology. 2005;112:848–854.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al-Mezaine HS, Hemachandran S, et al. Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt–Koyanagi–Harada disease. Eur J Ophthalmol. 2012;22:368–375.
   PubMed Web of Science ®Google Scholar
• Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647–652.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhou H, Yang P, et al. Longitudinal quantification of aqueous flare and cells in Vogt–Koyanagi–Harada disease. Br J Ophthalmol. 2008;92:182–185.
   PubMed Web of Science ®Google Scholar
• Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2008;145:480–486.
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan RP, Chan CK, et al. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt–Koyanagi–Harada disease. Eye (Lond). 2009;23:543–548.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Horie S, Bouchenaki N, et al. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2010;30:41–50.
   PubMedGoogle Scholar
• Inomata H, Sakamoto T. Immunohistochemical studies of Vogt–Koyanagi–Harada disease with sunset sky fundus. Curr Eye Res. 1990;9:35–40.
   PubMed Web of Science ®Google Scholar
• Midena E, Vujosevic S, Cavarzeran F; the Microperimetry Study Group. Normal values for fundus perimetry with the Microperimeter MP1. Ophthalmology. 2010;117:1571–1576.
   PubMed Web of Science ®Google Scholar
• Yang P, Fang W, Wang L, et al. Study of macular function by multifocal electroretinography in patients with Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol. 2008;146:767–771.
   PubMed Web of Science ®Google Scholar
• Giuliari GP, Pujari S, Shaikh M, et al. Microperimetry findings in patients with birdshot chorioretinopathy. Can J Ophthalmol. 2010;45:399–403.
   PubMed Web of Science ®Google Scholar